Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company focused on developing potential best-in-class medicines for serious and rare diseases, has announced the approval of Inducement Grants for five new employees. These grants, approved by the Compensation Committee of the company's Board of Directors, consist of non-qualified stock options to purchase 173,000 shares of Viridian's common stock.
The Inducement Grants, issued on September 3, 2024, are outside the company's Amended and Restated 2016 Equity Incentive Plan but remain subject to its terms. They have an exercise price equal to the closing price of Viridian's stock on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, contingent on continued employment.
Viridian Therapeutics (Nasdaq: VRDN), un'azienda biofarmaceutica impegnata nello sviluppo di potenziali farmaci di eccellenza per malattie gravi e rare, ha annunciato l'approvazione di Inducement Grants per cinque nuovi dipendenti. Questi premi, approvati dal Comitato per la Retribuzione del Consiglio di Amministrazione dell'azienda, consistono in opzioni su azioni non qualificate per l'acquisto di 173.000 azioni del capitale sociale di Viridian.
Le Inducement Grants, emesse il 3 settembre 2024, si trovano al di fuori del Piano di Incentivazione Patrimoniale del 2016 modificato e ristampato dell'azienda, ma rimangono soggette ai suoi termini. Hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni di Viridian nella data di concessione e si matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura in 36 rate mensili, a condizione di continuare a lavorare.
Viridian Therapeutics (Nasdaq: VRDN), una empresa biofarmacéutica centrada en desarrollar medicamentos potencialmente de mejor clase para enfermedades graves y raras, ha anunciado la aprobación de Inducement Grants para cinco nuevos empleados. Estas subvenciones, aprobadas por el Comité de Compensación de la Junta Directiva de la empresa, consisten en opciones sobre acciones no calificadas para comprar 173,000 acciones de las acciones ordinarias de Viridian.
Las Inducement Grants, emitidas el 3 de septiembre de 2024, están fuera del Plan de Incentivo de Capital Modificado y Restablecido de 2016 de la empresa, pero siguen estando sujetas a sus términos. Tienen un precio de ejercicio igual al precio de cierre de las acciones de Viridian en la fecha de concesión y se adquirirán en cuatro años, con un 25% adquiriéndose después de un año y el resto adquiriéndose en 36 pagos mensuales, condicionado a la continuación del empleo.
Viridian Therapeutics (Nasdaq: VRDN)는 심각하고 희귀한 질병을 위한 최고의 잠재적 의약품 개발에 중점을 둔 생명공학 회사로, 5명의 신입 직원에 대한 Inducement Grants 승인을 발표했습니다. 이 보상은 회사 이사회의 보상 위원회에서 승인되었으며, 173,000주를 구매할 수 있는 비자격 주식 선택권으로 구성되어 있습니다.
이 Inducement Grants는 2024년 9월 3일에 발행되었으며, 회사의 2016년 수정 및 재설계된 자본 인센티브 계획 외부에 있지만, 그 조건의 적용을 받습니다. 이들은 보조금 날짜의 Viridian 주식 종가에 해당하는 행사 가격을 가지며, 4년에 걸쳐 귀속됩니다, 1년 후에 25%가 귀속되고 나머지는 36개월에 걸쳐 월별로 귀속됩니다. 이는 계속 고용되는 것을 조건으로 합니다.
Viridian Therapeutics (Nasdaq: VRDN), une entreprise bio-pharmaceutique axée sur le développement de médicaments potentiellement de premier ordre pour les maladies graves et rares, a annoncé l'approbation de Inducement Grants pour cinq nouveaux employés. Ces subventions, approuvées par le Comité de Compensation du Conseil d'Administration de l'entreprise, consistent en options d'achat d'actions non qualifiées pour l'acquisition de 173 000 actions de l'action ordinaire de Viridian.
Les Inducement Grants, émises le 3 septembre 2024, sont en dehors du Plan d'Incentives en Capital Amendé et Révisé de l'entreprise, mais restent soumises à ses conditions. Elles ont un prix d'exercice égal au prix de clôture des actions Viridian à la date de la subvention et seront acquises sur une période de quatre ans, avec 25% devenant acquis après un an et le reste étant acquis en 36 versements mensuels, conditionnée à la poursuite de l'emploi.
Viridian Therapeutics (Nasdaq: VRDN), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung potenziell erstklassiger Medikamente für schwere und seltene Krankheiten konzentriert, hat die Genehmigung für Inducement Grants für fünf neue Mitarbeiter bekannt gegeben. Diese Zuschüsse, die vom Vergütungsausschuss des Vorstands genehmigt wurden, bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 173.000 Aktien des Stammkapitals von Viridian.
Die Inducement Grants, die am 3. September 2024 ausgegeben wurden, fallen außerhalb des geänderten und neu gefassten Eigenkapital-Incentive-Plans von 2016 des Unternehmens, unterliegen jedoch dessen Bedingungen. Sie haben einen Ausübungspreis, der dem Schlusskurs der Viridian-Aktien am Grant-Datum entspricht und werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig und der Rest in 36 monatlichen Raten fällig wird, vorbehaltlich der weiteren Beschäftigung.
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for VRDN-001, including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two planned global phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905733407/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares of Viridian Therapeutics (VRDN) stock were granted as Inducement Grants on September 3, 2024?
What is the vesting schedule for the Inducement Grants issued by Viridian Therapeutics (VRDN)?
How many new employees received Inducement Grants from Viridian Therapeutics (VRDN) in this announcement?
What is the exercise price of the Inducement Grants issued by Viridian Therapeutics (VRDN)?
